Oral anticoagulants for stroke prevention in atrial fibrillation
Research output: Contribution to journal › Article
Colleges, School and Institutes
The availability of 4 non–vitamin K oral anticoagulants (NOACs), that is, dabigatran, rivaroxaban, apixaban, and edoxaban, has changed the landscape of stroke prevention in patients with atrial fibrillation. This review article provides an overview of the 4 phase III studies that have compared these NOACs, examining major outcomes of efficacy and safety. A range of practical questions relating to the NOACs have emerged, including topics such as patient selection, treating patients with renal impairment, treating elderly patients, and combining anticoagulant therapy with antiplatelet drugs. We also address the interaction of various patient characteristics with the treatments and suggest the features can assist the physician in the choice of a particular NOAC for a particular patient(s).
|Journal||Current Problems in Cardiology|
|Early online date||17 Jul 2014|
|Publication status||Published - 1 Sep 2014|